Document Detail

Does Treatment Adherence Therapy reduce expense of healthcare use in patients with psychotic disorders? Cost-minimization analysis in a randomized controlled trial.
MedLine Citation:
PMID:  21999905     Owner:  NLM     Status:  Publisher    
BACKGROUND: Adherence interventions in psychotic disorders have produced mixed results. Even when an intervention improved adherence, benefits to patients were unclear. Treatment Adherence Therapy (TAT) also improved adherence relative to Treatment As Usual (TAU), but it had no effects on symptoms or quality of life. TAT may or may not reduce healthcare costs. AIM: To determine whether TAT reduces the use of healthcare resources, and thus healthcare costs. METHOD: Randomized controlled trial of TAT versus TAU with 98 patients. Interviews were conducted at baseline (T0), six months later, when TAT had been completed (T1) and at six-month follow-up (T2). We have used admission data and part of the Trimbos/iMTA questionnaire for Costs associated with Psychiatric Illness (TiC-P). We compared total costs in the TAT group with those in the control group with the help of multivariate analysis of covariance. RESULTS: TAT did not significantly minimize total costs. In the TAT group, the mean one-year health-treatment cost per patient (including TAT sessions) was € 23 003.64 (SD=19 317.95), whereas in the TAU group it was € 22 489.88 (SD=25 224.57) (F(1)=.652, p=.42). However, there were two significant differences at item-level, both with higher costs for the TAU group: psychiatric nurse contacts and legal proceedings for court-ordered admissions. CONCLUSIONS: Because TAT did not reduce total healthcare costs, it did not contribute to cost-minimization. Its benefits are therefore questionable. No other adherence intervention has included analysis of cost-effectiveness or cost-minimization.
J Gilden; A B P Staring; M van der Gaag; C L Mulder
Related Documents :
21704235 - Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-ana...
17867515 - Keratinocyte growth factor-2 on the proliferation of corneal epithelial stem cells in r...
8436235 - Wound dressing in major head and neck cancer surgery: a prospective randomized study of...
21979925 - Exploratory review of placebo characteristics reported in randomised placebo controlled...
21747845 - The efficacy and safety of propiverine hydrochloride in patients with overactive bladde...
668095 - Computer analysis of allergic histories taken by questionnaire.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-10-12
Journal Detail:
Title:  Schizophrenia research     Volume:  -     ISSN:  1573-2509     ISO Abbreviation:  -     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-10-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8804207     Medline TA:  Schizophr Res     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011 Elsevier B.V. All rights reserved.
Erasmus University Medical Center, Dr. Molewaterplein 50, 3015 GE Rotterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A systematic meta-review grading the evidence for non-genetic risk factors and putative antecedents ...
Next Document:  Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-bas...